Table 2.
Inflammatory markers at diagnosis (N = 298).
| Subgroups | IL-6 3 (pg/mL) | IL-8 (pg/mL) | IL-10 (pg/mL) | TNF-α 4 (pg/mL) | hsCRP 5 (μg/mL) |
|---|---|---|---|---|---|
| Concentrations | |||||
| Median (IQR 1) | 1.07 (0.98) | 5.68 (3.91) | 0.25 (0.21) | 2.21 (0.97) | 2.89 (5.89) |
| Male | 1.04 (1.06) | 5.50 (4.25) | 0.25 (0.21) | 2.23 (1.02) | 2.45 (5.51) |
| Female | 1.18 (0.95) | 6.09 (4.93) | 0.23 (0.17) | 2.18 (1.18) | 3.49 (5.88) |
| Stage of disease | |||||
| I | 1.12 (1.04) | 5.39 (5.33) | 0.23 (0.17) | 2.18 (0.81) | 2.96 (7.26) |
| II | 1.79 (0.83) | 7.01 (4.43) | 0.22 (0.25) | 2.27 (1.02) | 2.89 (5.70) |
| III | 1.03 (1.23) | 5.90 (4.13) | 0.27 (0.21) | 2.24 (1.30) | 2.73 (5.74) |
| No weekly NSAID 2 use | 1.07 (0.96) | 5.77 (4.33) | 0.24 (0.20) | 2.20 (1.06) | 2.89 (5.60) |
| Weekly NSAID use | 1.16 (1.08) | 5.64 (3.83) | 0.30 (0.17) | 2.61 (1.07) | 2.87 (5.38) |
1 IQR: interquartile range, 2 NSAID: non-steroidal anti-inflammatory drug, 3 IL: interleukin, 4 TNFα: tumour necrosis factor alpha, 5 hsCRP: high sensitive C-reactive protein.